AVITA Medical has appointed David McIntyre as chief financial officer (CFO). McIntyre will assume responsibility for overseeing the global finance and investor relations functions and will be based in AVITA’s Valencia office in California. Interim CFO Tim Rooney will continue in his role as AVITA Medical’s chief administrative officer with responsibility for global operations and supply chain management, program management, human resources, and information technology.
 
“David’s extensive background in global finance, operations and law, in combination with his experience as a senior executive and corporate advisor with life sciences and device companies listed on multiple stock exchanges, strengthens our leadership team at a pivotal time,” said Dr. Mike Perry, AVITA Medical’s CEO. “I want to thank Tim for his service as interim CFO and am delighted to have David on board as we position the company for continued growth, building on the successful U.S. commercial launch of the RECELL® System and further developing our pipeline across multiple indications.”
 
A seasoned executive with more than 20 years of experience, McIntyre has served in senior financial, legal and operational roles across multinational and growth-stage entities. Most recently, McIntyre served as a partner with Apple Tree Partners (ATP), a multibillion-dollar venture capture and growth equity fund focussed exclusively on life sciences. At ATP McIntyre was responsible for ATP’s medical device portfolio, together with various operating and Board functions, including acting as executive vice president, CFO, and head of Technical Operations at Braeburn Inc.
 
Prior to ATP, McIntyre was executive vice president, CFO and chief operating officer at HeartWare International Inc. where he oversaw HeartWare’s financial, supply chain and operating functions as it transitioned from pre-clinical stage through commercialization across more than 20 countries. Prior to HeartWare, McIntyre practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multi-national companies, including within the Rio Tinto Group of companies.
 
McIntyre earned a bachelor's degree in economics (accounting) from the University of Sydney (Australia), a bachelor of law degree from the University of Technology, Sydney (Australia) and an MBA (Fuqua Scholar) from Duke University. He is also a certified practicing accountant (CPA) and is admitted as a legal practitioner of the Supreme Court of New South Wales (in Australia).
 
AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing REGENERATIVE EPIDERMAL SUSPENSION (RES), an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.
 
AVITA Medical’s first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Data from randomized, controlled clinical trials conducted at major U.S. Burn Centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. In international markets, the company's products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.